These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 10769385

  • 1. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease.
    Lorenzo A, Yuan M, Zhang Z, Paganetti PA, Sturchler-Pierrat C, Staufenbiel M, Mautino J, Vigo FS, Sommer B, Yankner BA.
    Nat Neurosci; 2000 May; 3(5):460-4. PubMed ID: 10769385
    [Abstract] [Full Text] [Related]

  • 2. Amyloid-beta precursor protein mediates neuronal toxicity of amyloid beta through Go protein activation.
    Sola Vigo F, Kedikian G, Heredia L, Heredia F, Añel AD, Rosa AL, Lorenzo A.
    Neurobiol Aging; 2009 Sep; 30(9):1379-92. PubMed ID: 18187234
    [Abstract] [Full Text] [Related]

  • 3. Secreted amyloid precursor protein and holo-APP bind amyloid beta through distinct domains eliciting different toxic responses on hippocampal neurons.
    Kedikian G, Heredia F, Salvador VR, Raimunda D, Isoardi N, Heredia L, Lorenzo A.
    J Neurosci Res; 2010 Jun; 88(8):1795-803. PubMed ID: 20155808
    [Abstract] [Full Text] [Related]

  • 4. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
    van Groen T, Kiliaan AJ, Kadish I.
    Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
    [Abstract] [Full Text] [Related]

  • 5. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease.
    Mohmmad Abdul H, Sultana R, Keller JN, St Clair DK, Markesbery WR, Butterfield DA.
    J Neurochem; 2006 Mar; 96(5):1322-35. PubMed ID: 16478525
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice.
    Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ.
    Nat Neurosci; 2002 Dec; 5(12):1288-93. PubMed ID: 12402041
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
    Kandimalla KK, Wengenack TM, Curran GL, Gilles EJ, Poduslo JF.
    J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation.
    Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, Schmidt SD, Nixon RA, Frangione B, Levy E.
    Neurobiol Aging; 2004 Sep; 25(8):1033-43. PubMed ID: 15212828
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.